147

therapeutic
published patents

56

oncology
published patents

310

research tools

46

diagnostic
published patents

Our Technology Offers

Welcome to our Technology Offers website

You want access to an innovative offer which is based on the excellence of Inserm, the leading academic research and clinical institute dedicated to human health in Europe? Find out our technologies offers of patents and research tools: here is a sample of our patents.

Applications
Therapy areas
Download
More posts

Pyk2-based gene therapy gene therapy attenuates cognitive deficits

In the present invention it is shown that the inactivation of the Pyk2 gene does not alter hippocampal development but prevents hippocampal-dependent […]

Pyk2-based gene therapy attenuates cognitive deficits associated to

In the present invention it is shows that the inactivation of the Pyk2 gene does not alter hippocampal development but prevents hippocampal-dependent […]

Compounds targeting hsp110 protein for cancer treatment

HSP110 is involved in multiple tumorigenic processes, but no inhibitor was known to date. The inventors have identified for the first time HSP110 […]

Selective pharmacological inhibition of epac1 for the treatment of

The present invention relates to the treatment of idiopathic pulmonary fibrosis. Today, there is no cure for IPF. The inventors showed that EPAC1 […]

Correction of beta-thalassemia phenotype by genetically engineered

The present invention relates to a genetically modified hematopoietic stem cell (HSC) comprising, in at least one α-globin gene comprised in the […]

Anti-cathepsin d human antibody for triple negative breast cancer

Inventors have generated two human anti-cath-D scFv fragments cloned in the human IgG1 format (F1 and E2) that efficiently bind to human and […]

Antibodies specific for il20-rb and uses thereof for the treatment of

Chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity and mortality worldwide. Acute exacerbation of COPD (AE-COPD) in […]

Pd-1 antibodies and pd-l1 murin antibodies

The present invention relates to PD-1 and PD-L1 antibodies to treat cancer […]

Gaba administration induces alpha cell-mediated beta-like cell

GABA is an inducer of α-to-β-like cell conversion in vivo. This conversion induces α cell replacement mechanisms through the mobilization of […]

Novel b-raf inhibitors devoid of rapid metabolism and of binding to

The present invention relates to N-(3-(5-(pyrimidin-4-yl)thiazol-4-yl)phenylsulfonamide compounds which are useful as inhibitors of protein kinases, […]

More posts

You might also be interested in

Contact

Inserm Transfert

Research tool licensing team

researchtools@inserm-transfert.fr